Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

882 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Listening to patients, for the patients: The COVAD Study-Vision, organizational structure, and challenges.
Joshi M, Darooka N, Saha S, Dyball S, Sen P, Yaadav P, Javaid M, Kadam E, Shinjo SK, Dey D, Cavagna L, Makol A, Gutiérrez CET, Caballero Uribe CV, Kuwana M, Burmester GR, Ziade N, Wincup C, Andreoli L, Parodis I, Tan AL, Guillemin F, Knitza J, Wang G, Dalbeth N, Velikova T, Gracia-Ramos AE, Nikiphorou E, Day J, Chinoy H, Aggarwal R, Agarwal V, Gupta L; COVAD study group. Joshi M, et al. Among authors: burmester gr. Int J Rheum Dis. 2024 May;27(5):e15161. doi: 10.1111/1756-185X.15161. Int J Rheum Dis. 2024. PMID: 38720408
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, Lagunes I, Lippe R, Wung P, Gensler LS. Burmester GR, et al. Rheumatol Ther. 2024 Jun;11(3):737-753. doi: 10.1007/s40744-024-00671-4. Epub 2024 Apr 29. Rheumatol Ther. 2024. PMID: 38683479 Free PMC article.
Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD Studies.
Kadam E, Javaid M, Sen P, Saha S, Ziade N, Day J, Wincup C, Andreoli L, Parodis I, Tan AL, Shinjo SK, Dey D, Cavagna L, Chatterjee T, Knitza J, Wang G, Dalbeth N, Velikova T, Battista S, Cheng K, Boyd P, Kobert L, Gracia-Ramos AE, Mittal S, Makol A, Gutiérrez CET, Uribe CVC, Kuwana M, Burmester GR, Guillemin F, Nikiphorou E, Chinoy H, Aggarwal V, Gupta L; COVAD Study Group. Kadam E, et al. Among authors: burmester gr. Rheumatol Int. 2024 Apr 12. doi: 10.1007/s00296-024-05562-z. Online ahead of print. Rheumatol Int. 2024. PMID: 38609655
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, Boehncke WH, Esbensen BA, McInnes IB, McGonagle D, Winthrop KL, Balanescu A, Balint PV, Burmester GR, Cañete JD, Claudepierre P, Eder L, Hetland ML, Iagnocco A, Kristensen LE, Lories R, Queiro R, Mauro D, Marzo-Ortega H, Mease PJ, Nash P, Wagenaar W, Savage L, Schett G, Shoop-Worrall SJW, Tanaka Y, Van den Bosch FE, van der Helm-van Mil A, Zabotti A, van der Heijde D, Smolen JS. Gossec L, et al. Among authors: burmester gr. Ann Rheum Dis. 2024 May 15;83(6):706-719. doi: 10.1136/ard-2024-225531. Ann Rheum Dis. 2024. PMID: 38499325 Free PMC article.
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.
Rech J, Tascilar K, Hagen M, Kleyer A, Manger B, Schoenau V, Hueber AJ, Kleinert S, Baraliakos X, Braun J, Kiltz U, Fleck M, Rubbert-Roth A, Kofler DM, Behrens F, Feuchtenberger M, Zaenker M, Voll R, Venhoff N, Thiel J, Glaser C, Feist E, Burmester GR, Karberg K, Strunk J, Cañete JD, Senolt L, Filkova M, Naredo E, Largo R, Krönke G, D'Agostino MA, Østergaard M, Schett G. Rech J, et al. Among authors: burmester gr. Lancet. 2024 Mar 2;403(10429):850-859. doi: 10.1016/S0140-6736(23)02650-8. Epub 2024 Feb 13. Lancet. 2024. PMID: 38364841 Clinical Trial.
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trial.
Koehm M, Rossmanith T, Foldenauer AC, Herrmann E, Brandt-Jürgens J, Burmester GR, Kellner H, Kiltz U, Kofler DM, Rech J, Mojtahed-Poor S, Jonetzko C, Burkhardt H, Behrens F; MUST Investigator Group. Koehm M, et al. Among authors: burmester gr. Lancet Rheumatol. 2023 Jan;5(1):e14-e23. doi: 10.1016/S2665-9913(22)00329-0. Lancet Rheumatol. 2023. PMID: 38251504 Clinical Trial.
882 results